EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer

Wei Wang, Yisen Huang, Jianqiao Kong, Lin Lu, Qianxiu Liao, Jingtao Zhu, Tinghao Wang, Linghua Yan, Min Dai, Zhan Chen, Jun You

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03422-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Wei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA, Mutation, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xiamen Municipal Bureau of Science and Technology, Medical Innovation Project of Fujian Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The advent of circulating tumor DNA (ctDNA) technology has provided a convenient and noninvasive means to continuously monitor cancer genomic data, facilitating personalized cancer treatment. This study aimed to evaluate the supplementary benefits of plasma ctDNA alongside traditional tissue-based next-generation sequencing (NGS) in identifying targetable mutations and tumor mutational burden (TMB) in colorectal cancers (CRC).

Methods

Our study involved 76 CRC patients, collecting both tissue and plasma samples for NGS. We assessed the concordance of gene mutational status between ctDNA and tissue, focusing on actionable genes such as KRAS , NRAS , PIK3CA , BRAF , and ERBB2 . Logistic regression analysis was used to explore variables associated with discordance and positive mutation rates.

Results

In total, 26 cancer-related genes were identified. The most common variants in tumor tissues and plasma samples were in APC (57.9% vs 19.7%), TP53 (55.3% vs 22.4%) and KRAS (47.4% vs 43.4%). Tissue and ctDNA showed an overall concordance of 73.53% in detecting actionable gene mutations. Notably, plasma ctDNA improved detection for certain genes and gene pools. Variables significantly associated with discordance included gender and peritoneal metastases. TMB analysis revealed a higher detection rate in tissues compared to plasma, but combining both increased detection.

Conclusions

Our study highlights the importance of analyzing both tissue and plasma for detecting actionable mutations in CRC, with plasma ctDNA offering added value. Discordance is associated with gender and peritoneal metastases, and TMB analysis can benefit from a combination of tissue and plasma data. This approach provides valuable insights for personalized CRC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCirculating Tumor DNAMutationHigh-Throughput Nucleotide SequencingHumansMaleFemaleMiddle AgedAgedProto-Oncogene Proteins B-rafGTP PhosphohydrolasesProto-Oncogene Proteins p21(ras)Class I Phosphatidylinositol 3-KinasesBiomarkers, TumorAdultAged, 80 and overTumor Suppressor Protein p53Erb-b2 Receptor Tyrosine KinasesAdenomatous Polyposis Coli ProteinMembrane Proteins

Stichwörter der Autor:innen

Circulating tumor DNAColorectal cancerConcordancePositive mutation rateTumor mutational burden

Substanzen

Circulating Tumor DNAProto-Oncogene Proteins B-rafGTP PhosphohydrolasesProto-Oncogene Proteins p21(ras)Class I Phosphatidylinositol 3-KinasesBiomarkers, TumorTumor Suppressor Protein p53Erb-b2 Receptor Tyrosine KinasesAdenomatous Polyposis Coli ProteinMembrane Proteins

Autor:innen und Institutionen

  • The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Department of Gastroenterology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362002, Fujian, China.
  • Department of General Surgery, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, Hubei, China.
  • Colorectal Surgery Department, General Hospital of Ningxia Medical University, Yinchuan, 750001, Ningxia, China.
  • Department of Laboratory Medicine, Chengdu First People's Hospital, Chengdu, 610041, Sichuan, China.
  • The Third Clinical Medical College, Fujian Medical University, Xiamen, 361001, Fujian, China.

Förderung

  • Xiamen Municipal Bureau of Science and Technology
  • Medical Innovation Project of Fujian Provincial Health Commission

Zitieren

APA

Wang, W., Huang, Y., Kong, J., Lu, L., Liao, Q., Zhu, J., Wang, T., Yan, L., Dai, M., Chen, Z., & You, J. (2024). Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03422-7

Vancouver

Wang W, Huang Y, Kong J, Lu L, Liao Q, Zhu J, et al. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03422-7

BibTeX
@article{Wang2024,
  author = {Wang, Wei and Huang, Yisen and Kong, Jianqiao and Lu, Lin and Liao, Qianxiu and Zhu, Jingtao and Wang, Tinghao and Yan, Linghua and Dai, Min and Chen, Zhan and You, Jun},
  title = {Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03422-7}
}
Kostenlos starten →